Aldeyra’s Conjunctivitis Drug in Phase III Is a Sight for Sore Eyes

Aldeyra Therapeutics, headquartered in Lexington, Mass., announced positive results from its Phase III ALLEVIATE trial of reproxalap for allergic conjunctivitis. The trial evaluated reproxalap topical ophthalmic solution in two different concentrations, 0.25%, and 0.5%. The trial met the primary endpoint, which was the evaluation of ocular itch score (0 to 4) area under the curve from 10 to 60 minutes after the allergen challenge. In other words, the primary endpoint was less itchy eyes. It also met the key secondary endpoint, a two-point responder rate, which is a measure of clinical relevance. The trial evaluated 318 patients, about 100 per arm of the trial.